Cytokinetics, Inc. (Nasdaq: CYTK) has entered into a definitive agreement to sell 5.3 million shares of its Common Stock at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE